[Gene polymorphisms of renin-angiotensin system in patients with kidney diseases].
Blockade of the renin-angiotensin system (RAS), such as angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker, has been well appreciated as a renoprotective treatment in proteinuric glomerular diseases. However, not all patients with glomerular diseases respond well to this therapy. Single nucleotide polymorphisms (SNPs) in angiotensin-converting enzyme (ACE) and angiotensinogen may be involved in the inter-individual difference in the responsiveness to the renoprotective efficacy of the RAS blockade. This review focuses on the interface between genomics and therapeutics in the renin-angiotensin system in IgA nephropathy, the most prevalent form of primary glomerulonephritis and one of the major causes of end-stage renal disease in the world.
Narita
Ichiei
I
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences.
Gejyo
Fumitake
F
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000808:Angiotensinogen / Q000235:genetics*; D019405:Cytochrome P-450 CYP11B2 / Q000235:genetics*; D005922:Glomerulonephritis, IGA / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D012084:Renin-Angiotensin System / Q000235:genetics*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000808:Angiotensinogen; D019405:Cytochrome P-450 CYP11B2; D007703:Peptidyl-Dipeptidase A